KR
KRRO.US Korro Bio, Inc.
- Market cap
- USD 187M
- P/E
- -
- P/B
- 2.12x
- ROE
- -84.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KRRO.US undervalued?
Graham numberThe Graham number of Korro Bio, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Korro Bio, Inc. fundamental analysis
No fundamental analysis for Korro Bio, Inc. yet.
Korro Bio, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing pr…
Full company profileKorro Bio, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Korro Bio, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | 28.9M | 37.0M | 14.1M | 0.00 | 0.00 | 2.27M | 6.39M | 0.00 |
| Gross Profit | -531K | -654K | 12.1M | 35.4M | 10.2M | -2.51M | -3.63M | 2.27M | 2.11M | - |
| Operating Income | -16.3M | -18.9M | -20.7M | -27.6M | -35.5M | -59.0M | -84.5M | -91.9M | -87.3M | -78.7M |
| EBITDA | -19.5M | -18.4M | -17.9M | -24.9M | -33.9M | -56.5M | -80.9M | -88.3M | -83.1M | -77.2M |
| Net Income | -20.2M | -19.2M | -18.7M | -26.5M | -22.0M | -58.0M | -81.2M | -83.6M | -117M | -74.8M |
| EPS | -32 | -31 | -30 | -41 | -4.94 | -227 | -53 | -9.37 | -12 | -4.19 |
| Balance Sheet | ||||||||||
| Total Assets | 19.8M | 44.5M | 223M | 265M | 185M | 73.7M | 222M | 226M | 114M | 148M |
| Total Liabilities | 49.4M | 89.1M | 55.9M | 72.2M | 54.5M | 173M | 51.8M | 65.8M | 62.1M | 59.7M |
| Shareholders' Equity | -29.6M | -48.3M | 167M | 192M | 131M | -99.0M | 170M | 160M | 51.4M | 88.4M |
| Cash & Short-term Investments | 17.9M | 42.2M | 217M | 220M | 131M | 55.9M | 166M | 126M | 75.2M | 105M |
| Total Debt | 46.7M | 84.9M | - | 46.0M | 45.6M | 167M | 33.2M | 44.8M | 43.5M | 41.5M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -14.6M | -17.0M | 34.2M | -45.2M | -32.1M | -53.6M | -67.3M | -60.1M | -78.6M | -61.3M |
| Capital Expenditure | 1.86M | 436K | 1.06M | 6.67M | 4.45M | 5.21M | 7.84M | 17.9M | 518K | 113K |
| Free Cash Flow | -16.5M | -17.5M | 33.2M | -51.9M | -36.5M | -58.9M | -75.1M | -78.0M | -79.1M | -61.5M |
| Ratios | ||||||||||
| ROE | - | - | -11.2% | -13.8% | -16.8% | - | -47.8% | -52.1% | -228.0% | -84.6% |
| ROA | -102.3% | -43.0% | -8.4% | -10.0% | -11.8% | -78.7% | -36.6% | -36.9% | -103.3% | -50.5% |
| Net Profit Margin | - | - | -64.8% | -71.7% | -156.1% | - | - | -3,680.4% | -1,834.5% | - |
| Debt to Equity | - | - | - | 0.24x | 0.35x | - | 0.20x | 0.28x | 0.85x | 0.47x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Korro Bio, Inc. dividends
Korro Bio, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:50 on Nov 6, 2023.
Who owns Korro Bio, Inc.
- Insiders 2.05%
- Institutions 97.95%
- Public & others 0.00%
- Shares outstanding 13.7M
- Free float 7.87M
Top funds holding KRRO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 327K | 2.38% | +4.95% | Sep 2026 |
| iShares Russell 2000 ETF | 281K | 2.05% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 124K | 0.90% | +1.68% | Aug 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 106K | 0.78% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 82.5K | 0.60% | 0.00% | Oct 2026 |
| F/m Emerald Life Sciences Innovation ETF | 65.9K | 0.48% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 64.5K | 0.47% | +0.70% | Sep 2026 |
| Fidelity Extended Market Index | 43.1K | 0.31% | -30.30% | Sep 2026 |
| iShares Micro-Cap ETF | 33.5K | 0.24% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 28.6K | 0.21% | +0.12% | Sep 2026 |
| Bridge Builder Small Cap Fund | 28.5K | 0.21% | +907.67% | Oct 2026 |
| Schwab Small Cap Index | 26.9K | 0.20% | 0.00% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 21.0K | 0.15% | -5.93% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 20.8K | 0.15% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 20.1K | 0.15% | -0.05% | Sep 2026 |
| Fidelity Series Total Market Index | 18.1K | 0.13% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 17.8K | 0.13% | -0.39% | Oct 2026 |
| Avantis US Small Cap Equity ETF | 15.8K | 0.12% | 0.00% | Oct 2026 |
| Nuveen Small Cap Blend Idx R6 | 14.9K | 0.11% | 0.00% | Sep 2026 |
| Vanguard VIF Small Co Gr | 14.6K | 0.11% | 0.00% | Sep 2026 |
Top institutions holding KRRO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Lynx1 Capital Management, LP | 1.54M | 11.21% | 0.00% | Jun 2026 |
| Nantahala Capital Management, LLC | 1.32M | 9.62% | +100.00% | Jun 2026 |
| NEA Management Company, LLC | 1.30M | 9.46% | 0.00% | Jun 2026 |
| VR Adviser, LLC | 1.01M | 7.35% | 0.00% | Jun 2026 |
| Atlas Venture Life Science Advisors, LLC | 963K | 7.02% | -15.32% | Jun 2026 |
| Balyasny Asset Management LLC | 952K | 6.93% | -8.49% | Jun 2026 |
| BlackRock Inc | 818K | 5.96% | +77.74% | Jun 2026 |
| Affinity Asset Advisors, LLC | 707K | 5.15% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 541K | 3.94% | +136.85% | Jun 2026 |
| ADAR1 Capital Management LLC | 540K | 3.93% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 455K | 3.31% | +46.27% | Jun 2026 |
| Driehaus Capital Management LLC | 450K | 3.28% | 0.00% | Jun 2026 |
| TCG Crossover Management, LLC | 416K | 3.03% | 0.00% | Jun 2026 |
| Kalehua Capital Management LLC | 405K | 2.95% | +270.32% | Jun 2026 |
| Siren, L.L.C. | 348K | 2.53% | 0.00% | Jun 2026 |
| AQR Capital Management LLC | 299K | 2.18% | +11.66% | Jun 2026 |
| Geode Capital Management, LLC | 297K | 2.16% | +70.97% | Jun 2026 |
| 72 Investment Holdings, LLC | 277K | 2.02% | 0.00% | Jun 2026 |
| State Street Corp | 233K | 1.69% | +65.73% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 224K | 1.63% | +50.48% | Jun 2026 |
Korro Bio, Inc. company profile
- Company name
- Korro Bio, Inc.
- Ticker
- KRRO.US
- Exchange
- USA Stocks
- Listed since
- Nov 6, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 58
- Fiscal year end
- December
- Address
- 60 First Street, Cambridge, MA, United States, 02141
- Phone
- 617 468 1999
- Website
- korrobio.com
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Korro Bio, Inc. management
10- Dr. Ram Aiyar MBA, Ph.D.CEO, President, Interim CFO, Principal Financial Officer & Director · born 1978
- Dr. Jean-Francois Formela M.D., MBACo-Founder & Director · born 1957
- Dr. Loic Vincent Ph.D.Chief Scientific Officer
- Dr. Jeffrey M. Cerio J.D., Pharm.D.Senior VP, General Counsel & Corporate Secretary
- Dr. Andrew Fraley Ph.D.Co-Founder & Advisor
- Dr. Joshua Rosenthal Ph.D.Co-Founder & Advisor
- Mr. Todd Chappell M.B.A.Chief Operating Officer · born 1973
- Mr. Oliver DolanSenior VP of Finance & Principal Accounting Officer · born 1983
- Ms. Stephanie EngelsChief People Officer
- Dr. Gaozhong Zhu Ph.D.SVP of Chemistry, Manufacturing and Controls & Technical Operations